Background
==========

Cancer is a multifactor disease caused by complex interactions between environmental and genetic factors \[[@B1]\]. The incidence of different cancer varies widely in different populations which may be largely attributed to lifestyle and genetic background \[[@B2]\]. Environmental factors such as smoking and exposure to carcinogens lead to direct damage to DNA \[[@B3]\]. To a certain extent, these damages can be repaired by endogenous DNA repair systems \[[@B4]\]. However, genetic variations in these systems may result in reduced repair capability and the defect allow DNA damage to accumulate which leads to permanent mutations in the genome and contributes to carcinogenesis.

Among DNA repair systems, base excision repair (BER) pathway is responsible for repairing small lesions such as oxidative damage, alkylation, or methylation \[[@B5]\]. AP Endonuclease 1 (APE1, also known as APE, APEX, HAP1, and REF-1) is a multifunctional protein and plays a central role in the BER pathway through hydrolyzing the phosphodiester backbone immediately 5\' to the AP site \[[@B5],[@B6]\]. APE1 can act as a 3\'-phosphodiesterase to initiate repair of DNA single strand breaks, which are produced either directly by reactive oxygen species or indirectly through the enzymatic removal of damaged bases \[[@B7],[@B8]\]. APE1 is also known as a transcriptional coactivator for numerous transcription factors involved in cancer development \[[@B9]\] and is considered as a promising tool for anticancer therapy \[[@B10]\].

The human *APE1*is located on chromosome 14q11.2-q12 and consists of five Exons spanning 2.21 kb \[[@B11]\]. Till now, many epidemiological studies suggested genetic variations in *APE1*may confer individuals\' susceptibility to cancer. A total of 18 single nucleotide polymorphisms (SNPs) in *APE1*have been identified \[[@B11]\], of which, two functional SNPs (−656 T \> G in the promoter region, rs1760944 and 1349 T \> G in the fifth Exon, rs1130409) have been wildly investigated. In lung cancer, Lu et al. and Lo et al. reported that −656 T \> G polymorphism influenced the transcriptional activity of *APE1*and contributed to lung cancer susceptibility \[[@B12],[@B13]\]. Although one study in bladder cancer supported the association \[[@B14]\], it has not been replicated in some others \[[@B15]-[@B17]\]. As to 1349 T \> G polymorphism, functional studies suggested that the G allele may have altered endonuclease and DNA-binding activity, reduced ability to communicate with other BER proteins and decreased capacity to repair DNA oxidative damage \[[@B18],[@B19]\]. Recently, numerous studies investigated the influence of 1349 T \> G polymorphism on cancer risk; however, the results of these studies remain inconclusive.

To reveal a small effect of the polymorphisms on cancer risk, a single study might be underpowered, particularly for studies with relatively small sample size. Meta-analysis is a statistical technique for combining results from different studies to produce a single estimate of the major effect with enhanced precision. It is considered a powerful tool to summarize inconclusive results from different studies. To clarify the effect of the *APE1*-656 T \> G and 1349 T \> G polymorphisms on cancer risk; we conducted a meta-analysis of all eligible case-control studies that have been published. Before analysis, we tested whether these two SNPs were in linkage disequilibrium with each other in Europeans and Asians, and the data from HapMap database suggested the two SNPs were not correlated (*D\'*= 0.335, r^2^= 0.071 for Europeans and *D\'*= 0.409, r^2^= 0.071 for Asians).

Methods
=======

Identification of eligible studies
----------------------------------

A literature search of the PubMed and EMBASE databases (updated to June, 2011) was conducted using combinations of the following terms: \"APE1\", \"APEX\", \"HAP1\", \"REF-1\", \"polymorphism\", and \"cancer\". The search was limited to English language papers. All studies that evaluated the association between polymorphisms of *APE1*and cancer risk were retrieved, and their bibliographies were checked for other relevant publications. Studies that were included in the meta-analysis had to meet all of the following criteria: 1) evaluate the *APE1 −*656T \> G and 1349T \> G polymorphisms and cancer risk, 2) use a case-control design, 3) contain available genotypes frequency for estimating an odds ratio (OR) with a 95% confidence intervals (CIs), 4) genotype distributions in control consistent with Hardy-Weinberg equilibrium (HWE). Accordingly, abstracts and reviews studies that that did not report genotype frequency were excluded. When more than one of the same patient population was included in several publications, only the most recent or complete study was used in this meta-analysis.

Data extraction
---------------

Information was carefully extracted from all eligible publications independently by two of the authors according to the selection criteria. In case of disagreement, a third reviewer assessed the articles. The following items were collected: author name, year of publication, country of origin, ethnicity, source of the controls, genotyping method, cancer type, total number of cases and controls, and genotype distributions in cases and controls.

Statistical analysis
--------------------

The strength of associations between *APE1*polymorphisms and cancer risk were measured by ORs with 95%CIs. We examined the association between the *APE1 −*656 T \> G and 1349 T \> G polymorphisms and cancer risk in homozygote comparison (GG vs. TT), heterozygote comparison (TG vs. TT), the dominant genetic model (TG/GG vs. TT), and the recessive genetic model (GG vs. TT/TG). Stratified analyses were also carried out by ethnicity, cancer type and source of controls.

Heterogeneity assumption was evaluated with a chi-square-based Q-test. If the *P*value is greater than 0.05 of the Q-test, which indicates a lack of heterogeneity among studies, the summary OR estimate of each study was calculated by a fixed effects model (the Mantel-Haenszel method) \[[@B20]\]; otherwise, the random-effects model (the DerSimoniane and Laird method) \[[@B21]\] was performed. Sensitivity analyses were also performed to assess the stability of the results. Funnel plots and Egger\'s linear regression test were used to provide diagnosis of the potential publication bias. All statistical analysis were done with the Stata software (version 11.0; StataCorp LP, College Station, TX), using two-sided *P*values.

Results
=======

Study selection and characteristics in the meta-analysis
--------------------------------------------------------

A total of 37 eligible studies from 32 articles met the inclusion criteria \[[@B12]-[@B17],[@B22]-[@B47]\]. In total, 5,139 cases and 5,201 controls from 8 studies for −656 T \> G polymorphism \[[@B12]-[@B17]\], and 14,222 cases and 19,746 controls from 35 studies for 1349 T \> G polymorphism were included in the pooled analyses \[[@B12]-[@B14],[@B16],[@B17],[@B22]-[@B47]\]. The characteristics of selected studies are presented in Table [1](#T1){ref-type="table"}. The distribution of genotypes in the controls of all studies was consistent with HWE. Of the 8 studies for −656 T \> G polymorphism, 3 investigated lung cancer and 2 investigated bladder cancer, and the other 3 articles investigated individually brain cancer, renal cell cancer and colorectal adenoma. Six of these studies were conducted in Asian populations and 2 in European populations. Among the 35 studies for 1349 T \> G polymorphism, there were 7 bladder cancer studies, 4 breast cancer studies, 4 colorectal cancer studies, 2 head and neck cancer studies, 9 lung cancer studies and 9 others studies including oesophageal cancer, pancreatic cancer, leukaemia, prostate cancer, biliary tract cancer, thyroid cancer, renal cell cancer and gastric cancer. Ten of these studies were from Asians, 23 were from Europeans and 2 were studies of mixed populations.

###### 

Characteristics of populations and cancer types of the studies included in the meta-analysis

  Study                Country         Ethnicity   Cancer type            Sample size case/control   Source of controls   Genotyping method          Polymorphisms
  -------------------- --------------- ----------- ---------------------- -------------------------- -------------------- -------------------------- --------------------------
  Misra 2003 ^20^      Finland         European    Lung cancer            310/302                    Population           TaqMan                     1349 T \> G
                                                                                                                                                     
  Popanda 2004 ^21^    Germany         European    Lung cancer            459/457                    Hospital             Rapid capillary PCR        1349 T \> G
                                                                                                                                                     
  Hao 2004 ^22^        China           Asian       Oesophageal cancer     409/478                    Population           PCR-RFLP                   1349 T \> G
                                                                                                                                                     
  Ito 2004 ^23^        Japan           Asian       Lung cancer            178/449                    Hospital             PCR-RFLP                   1349 T \> G
                                                                                                                                                     
  Shen 2005 ^24^       China           Asian       Lung cancer            117/113                    Population           TaqMan                     1349 T \> G
                                                                                                                                                     
  Moreno 2006 ^25^     Spain           European    Colorectal cancer      359/312                    Hospital             Arrayed primer extension   1349 T \> G
                                                                                                                                                     
  Jiao 2006 ^26^       USA             European    Pancreatic cancer      367/330                    Hospital             Allele-specific PCR        1349 T \> G
                                                                                                                                                     
  Terry 2006 ^27^      USA             European    Bladder cancer         229/207                    Hospital             MALDI-TOF                  1349 T \> G
                                                                                                                                                     
  Wu 2006 ^28^         USA             European    Bladder cancer         596/590                    Hospital             TaqMan                     1349 T \> G
                                                                                                                                                     
  Zhang 2006 ^29^      USA             European    Breast cancer          1529/1207                  Population           TaqMan                     1349 T \> G
                                                                                                                                                     
  Matullo 2006 ^30^    Multi-country   European    Breast cancer          124/1094                   Population           TaqMan                     1349 T \> G
                                                                                                                                                     
                                                   Lung cancer            116/1094                   Population           TaqMan                     1349 T \> G
                                                                                                                                                     
                                                   Head and neck cancer   82/1094                    Population           TaqMan                     1349 T \> G
                                                                                                                                                     
                                                   Leukemia               169/1094                   Population           TaqMan                     1349 T \> G
                                                                                                                                                     
  Chen 2006 ^31^       USA             Mixed       Prostate cancer        351/329                    Hospital             PCR-RFLP                   1349 T \> G
                                                                                                                                                     
  Li 2007 ^32^         USA             European    Head and neck cancer   830/854                    Hospital             PCR-RFLP                   1349 T \> G
                                                                                                                                                     
  Berndt 2007 ^14^     USA             European    Colorectal cancer      767/773                    Population           TaqMan                     1349 T \> G, −656 T \> G
                                                                                                                                                     
  Figueroa 2007 ^15^   Spain           European    Bladder cancer         1150/1149                  Hospital             TaqMan                     1349 T \> G, −656 T \> G
                                                                                                                                                     
  Andrew 2008 ^33^     USA/Italy       European    Bladder cancer         911/1165                   Population           SNP mass-tagging system    1349 T \> G
                                                                                                                                                     
  Pardini 2008 ^34^    Czech           European    Colorectal cancer      531/530                    Hospital             TaqMan                     1349 T \> G
                                                                                                                                                     
  Mitra 2008 ^35^      India           European    Bladder cancer         150/225                    Population           PCR-RFLP                   1349 T \> G
                                                                                                                                                     
  Tse 2008 ^36^        USA             European    Colorectal cancer      311/454                    Hospital             TaqMan                     1349 T \> G
                                                                                                                                                     
  Huang 2008 ^37^      China           Asian       Biliary tract cancer   409/783                    Population           TaqMan                     1349 T \> G
                                                                                                                                                     
  Chiang 2008 ^38^     China           Asian       Thyroid cancer         283/469                    Hospital             TaqMan                     1349 T \> G
                                                                                                                                                     
  Smith 2008 ^39^      USA             Asian       Breast cancer          372/480                    Hospital             Arrayed primer extension   1349 T \> G
                                                                                                                                                     
  Gangwar 2009 ^40^    India           European    Bladder cancer         206/250                    Hospital             TaqMan                     1349 T \> G
                                                                                                                                                     
  Agachan 2009 ^41^    Turkey          European    Lung cancer            98/67                      Hospital             PCR-RFLP                   1349 T \> G
                                                                                                                                                     
  Lo 2009 ^11^         China           Asian       Lung cancer            729/722                    Hospital             Arrayed primer extension   1349 T \> G, −656 T \> G
                                                                                                                                                     
  Lu 2009 ^10^         China           Asian       Lung cancer            500/517                    Population           Illumina                   1349 T \> G, −656 T \> G
                                                                                                                                                     
                                                   Lung cancer            572/547                    Hospital             SNPscan                    −656 T \> G
                                                                                                                                                     
  Wang 2010 ^12^       China           Asian       Bladder cancer         234/253                    Hospital             PCR-RFLP                   1349 T \> G, -656 T \> G
                                                                                                                                                     
  Deng 2010 ^42^       China           Asian       Lung cancer            315/314                    Population           RT-PCR                     1349 T \> G
                                                                                                                                                     
  Palli 2010 ^43^      Italy           European    Gastric cancer         298/546                    Population           TaqMan                     1349 T \> G
                                                                                                                                                     
  Jelonek 2010 ^44^    Poland          European    Colorectal cancer      113/153                    Hospital             PCR-RFLP                   1349 T \> G
                                                                                                                                                     
                                                   Breast cancer          91/412                     Hospital             PCR-RFLP                   1349 T \> G
                                                                                                                                                     
  Zhou 2011 ^13^       China           Asian       Brain cancer           750/816                    Hospital             MassARRAY                  −656 T \> G
                                                                                                                                                     
  Cao 2011 ^45^        China           Asian       Renal cell carcinoma   612/632                    Hospital             TaqMan                     1349 T \> G, -656 T \> G

*RFLP*, restriction fragment length polymorphism; PCR, polymerase chain reaction; MALDI-TOF, matrix assisted laser desorption/ionization time-of-flight; SNP, single nucleotide polymorphism; C, cytosine; T, thymine; PCR-CTPP, polymerase chain reaction with confronting two-pair primers.

The −656 T \> G polymorphism
----------------------------

The frequency of the G allele varied widely across the 8 studies, ranging from 0.44 to 0.64. The average frequency of the G allele in Asian populations was 0.45, which was lower than that in European populations (0.62). The difference was statistical significant (*P*\< 0.001).

Overall, there was evidence of an association between decreased cancer risk and the variant genotypes in different genetic models when all the eligible studies were pooled into the meta-analysis. As show in Table [2](#T2){ref-type="table"}, compared with the wild-type homozygote genotype, the homozygote variant genotype GG was associated with a statistically significant decreased risk of all types of cancer (OR = 0.81, 95%CI = 0.67-0.97). Besides, significant main effects were also observed both in dominant and recessive models (OR = 0.89, 95%CI = 0.81-0.97 and OR = 0.90, 95%CI = 0.82-0.98). In the stratified analysis by populations, as shown in Table [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}, the effect was remain in studies of Asian populations (homozygote comparison: OR = 0.75, 95%CI = 0.65-0.86; heterozygote comparison: OR = 0.89, 95%CI = 0.80-0.99; dominant model: OR = 0.85, 95%CI = 0.77-0.94 and recessive model: OR = 0.81, 95%CI = 0.71-0.91). In the stratified analysis by cancer type, as shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}, the effect was remain in lung cancer studies (homozygote comparison: OR = 0.65, 95%CI = 0.54-0.79; heterozygote comparison: OR = 0.83, 95%CI = 0.72-0.97; dominant model: OR = 0.78, 95%CI = 0.68-0.89 and recessive model: OR = 0.72, 95%CI = 0.61-0.86). Further subgroup analyses were not performed because of limited data for this polymorphism.

###### 

Meta-analysis of the *APE1*−656 T \> G polymorphism and cancer risk

  Variables        n \*   GG vs. TT          TG vs. TT   GG/TG vs. TT       GG vs. TT/TG                                                 
  ---------------- ------ ------------------ ----------- ------------------ -------------- ------------------ ------- ------------------ -------
  Total            8      0.81 (0.67-0.97)   0.015       0.92 (0.83-1.01)   0.340          0.89 (0.81-0.97)   0.084   0.90 (0.82-0.98)   0.059
                                                                                                                                         
  Ethnicities                                                                                                                            
                                                                                                                                         
  Asian            6      0.75 (0.65-0.86)   0.057       0.89 (0.80-0.99)   0.255          0.85 (0.77-0.94)   0.093   0.81(0.71-0.91)    0.252
                                                                                                                                         
  European         2      1.04 (0.85-1.28)   0.703       1.01 (0.83-1.24)   0.692          1.03 (0.85-1.24)   0.680   1.03 (0.90-1.18)   0.891
                                                                                                                                         
  Cancer types                                                                                                                           
                                                                                                                                         
  Lung cancer      3      0.65 (0.54-0.79)   0.857       0.83 (0.72-0.97)   0.469          0.78 (0.68-0.89)   0.602   0.72 (0.61-0.86)   0.799
                                                                                                                                         
  Bladder cancer   2      0.88 (0.70-1.12)   0.045       0.89 (0.72-1.11)   0.583          0.88 (0.71-1.08)   0.097   0.97 (0.82-1.14)   0.086
                                                                                                                                         
  Others           3      1.00 (0.83-1.19)   0.276       1.03 (0.88-1.19)   0.340          1.02 (0.88-1.15)   0.397   0.98 (0.85-1.13)   0.437

\* Number of comparisons

^†^Random-effects model was used when P value for heterogeneity test \< 0.05; otherwise, fix-effects model was used

^‡^P value of Q-test for heterogeneity test

![**Meta-analysis with a random-effects model for the association between cancer risk and the *APE1*−656 T \> G polymorphism stratified by ethnicity (TG/GG *vs*. TT)**. OR, odds ratio; CI, confidence interval; I-squared, measure to quantify the degree of heterogeneity in meta-analyses.](1471-2407-11-521-1){#F1}

![**Meta-analysis with a random-effects model for the association between cancer risk and the *APE1*-656 T \> G polymorphism stratified by cancer types (TG/GG *vs*. TT)**. OR, odds ratio; CI, confidence interval; I-squared, measure to quantify the degree of heterogeneity in meta-analyses.](1471-2407-11-521-2){#F2}

Heterogeneity was observed in homozygote comparison (*P*~heterogeneity~= 0.015) for the main effects. Therefore, we conducted sensitivity analyses to locate the source of heterogeneity, and the results suggested that two studies \[[@B16],[@B47]\] were the main origin of the heterogeneity. The heterogeneity was effectively removed after exclusion of these studies (*P*~heterogeneity~= 0.123, 0.355 and 0.163, respectively for homozygote comparison, dominant and recessive model). The results were not materially altered after exclusion of these studies, suggesting the results of this meta-analysis were stable.

As shown in Figure [3](#F3){ref-type="fig"}, the shape of the funnel plots seemed asymmetrical in the recessive model, suggesting the presence of publication bias. The Egger\'s test showed obvious evidence of publication bias (t = −3.01, *P*= 0.024, recessive model). To adjust for this bias, a trim-and-fill method developed by Duval and Tweedie \[[@B48]\] was conducted, the adjusted estimates obtained by using random-effects model was OR of 0.87 (0.76-0.99). Meta-analysis with or without the trim-and-fill method did not draw different conclusions, indicating that our results were statistically robust.

![**Begg\'s funnel plot of publication bias test (−656 T \> G; GG *vs*. TT/TG)**. Each point represents a separate study for the indicated association. Log (OR), natural logarithm of OR; Horizontal line, mean effect size.](1471-2407-11-521-3){#F3}

The 1349 T \> G polymorphism
----------------------------

The frequency of the G allele varied widely across the 39 studies, ranging from 0.20 to 0.52. However, no significant difference in the frequency distribution of the G allele between Asian and European populations were observed (frequencies of G allele were 0.42 and 0.44 in Asian and European populations, respectively; *P*= 0.514).

As shown in Table [3](#T3){ref-type="table"}, the results did not suggest any statistical evidence of an association between the 1349 T \> G polymorphism and overall cancer risk (Table [3](#T3){ref-type="table"}). In the subgroup analysis by ethnicities, source of controls and cancer types, still no significant association was observed (Table [3](#T3){ref-type="table"}). No publication bias was detected by either the funnel plot or the Egger test (GG vs. TT: t = 0.33, *P*= 0.745; TG vs.TT: t = 1.22, *P*= 0.233; TG/GG vs. TT: t = 1.29, *P*= 0.244; GG vs. TT/TG: t = 0.02, *P*= 0.985).

###### 

Meta-analysis of the *APE1*1349 T \> G polymorphism and cancer risk

  Variables              n \*   GG vs. TT          TG vs. TT   GG/TG vs. TT       GG vs. TT/TG                                                 
  ---------------------- ------ ------------------ ----------- ------------------ -------------- ------------------ ------- ------------------ -------
  Total                  35     1.05 (0.95-1.16)   0.001       1.04 (0.96-1.12)   0.004          1.04 (0.97-1.13)   0.000   1.03 (0.96-1.11)   0.022
                                                                                                                                               
  Ethnicities                                                                                                                                  
                                                                                                                                               
  Asian                  10     1.05 (0.93-1.20)   0.051       0.97 (0.88-1.07)   0.657          0.99 (0.90-1.08)   0.427   1.08 (0.92-1.28)   0.035
                                                                                                                                               
  European               23     1.05 (0.92-1.19)   0.001       1.09 (0.99-1.20)   0.003          1.09 (0.98-1.21)   0.000   1.00 (0.94-1.07)   0.062
                                                                                                                                               
  Source of controls                                                                                                                           
                                                                                                                                               
  Population-based       15     1.01 (0.92-1.11)   0.130       1.07 (0.95-1.21)   0.010          1.06 (094-1.20)    0.004   0.98 (0.90-1.07)   0.335
                                                                                                                                               
  Hospital-based         20     1.07 (0.92-1.24)   0.000       1.02 (0.93-1.11)   0.048          1.03 (0.93-1.15)   0.002   1.06 (0.95-1.20)   0.014
                                                                                                                                               
  Cancer types                                                                                                                                 
                                                                                                                                               
  Lung cancer            9      1.08 (0.85-1.38)   0.017       0.99 (0.84-1.17)   0.059          1.03 (0.85-1.25)   0.007   1.04 (0.92-1.19)   0.086
                                                                                                                                               
  Bladder cancer         7      0.96 (0.83-1.09)   0.312       1.01 (0.91-1.12)   0.376          0.99 (0.90-1.10)   0.453   0.95 (0.85-1.07)   0.360
                                                                                                                                               
  Colorectal cancer      4      0.93 (0.55-1.57)   0.001       1.05 (0.78-1.41)   0.025          1.01 (0.72-1.43)   0.003   0.93 (0.63-1.39)   0.003
                                                                                                                                               
  Breast cancer          4      1.20 (0.82-1.76)   0.042       1.19 (0.76-1.86)   0.000          1.23 (0.79-1.92)   0.000   1.06 (0.92-1.23)   0.345
                                                                                                                                               
  Head and neck cancer   2      1.03 (0.80-1.32)   0.306       1.00 (0.81-1.23)   0.242          1.01 (0.83-1.23)   0.202   1.03 (0.83-1.27)   0.621
                                                                                                                                               
  Others                 9      1.07 (0.94-1.23)   0.156       1.05 (0.94-1.16)   0.754          1.05 (0.96-1.16)   0.609   1.05 (0.93-1.18)   0.111

\* Number of comparisons

^†^Random-effects model was used when P value for heterogeneity test \<0.05; otherwise, fix-effects model was used

^‡^P value of Q-test for heterogeneity test

Discussion
==========

To data, numerous studies have been carried out to investigate whether polymorphisms in *APE1*are associated with the risk of cancer; however, the data have yielded conflicting results. In the present study, to derive a more precise estimation of the relationship, we performed a meta-analysis of 37 published studies including 5,139 cases and 5,201 controls for *APE1*−656 T \> G polymorphism, and 14,222 cases and 19,746 controls for *APE1*1349 T \> G polymorphism. Our meta-analysis indicated that variant genotypes (GG and TG/GG) of −656 T \> G polymorphism was associated with a significant decrease in the overall risk of cancer, especially for lung cancer and Asians. However, the 1349 T \> G polymorphism did not appear to have significant influence on the overall risk of cancer.

Apurinic/apyrimidinic (AP) sites are common mutagenic and cytotoxic DNA lesions which caused by the loss of normal bases \[[@B49]\]. *APE1*had been extensively studied as the major AP endonuclease involved in the repair of AP sites through both its endonuclease and phosphodiesterase activities \[[@B7]\]. Alteration in the expression of *APE1*may influence its capacity to repair DNA damage. Several lines of evidence support that the −656 T \> G polymorphism plays a role in influencing the promoter activity of *APE1*. Using in vitro promoter assay, Lo et al. found that the −656 G allele had a significantly higher transcriptional activity than that of the −656 T allele and individuals with the −656 G allele were at a decreased risk for lung cancer \[[@B13]\]. In their view, the \"higher production\" genotype for *APE1*might offer protection against the development of lung cancer \[[@B13]\]. Nearly at the same time, Lu et al. also reported a similar protective effect of the −656 G allele against lung cancer risk in two independent studies \[[@B12]\]. However, they showed that the G allele attenuated the binding of Oct-1 to the promoter region of *APE1*and resulted in decreased transcriptional activity. Given the disparity between these functional studies, the mechanism underlying the regulation of *APE1*by this polymorphism may be still required further investigation. Nevertheless, our meta-analysis showed that individuals with the variant genotypes (GG or GG/TG) of −656 T \> G polymorphism were associated with a decreased cancer risk than those with the TT genotype. Although publication bias was observed in the recessive genetic model, our meta-analysis with or without trim-and-fill method did not draw different conclusions, suggesting that our results were statistically robust.

In the subgroup analysis by cancer type, we found that individuals with the variant genotypes of −656 T \> G polymorphism were associated with decreased lung cancer risk. However, the result should be interpreted with caution. Because, only four types of cancer (lung cancer, bladder cancer, brain tumor and colorectal adenoma) were included and the studies of each type were very limited, which may have insufficient power to reveal a reliable association. In the subgroup analysis by ethnicity, the results suggested that the association was more apparent among Asian populations. Several reasons may lead to the ethnic difference. First, differences in genetic background may cause the difference. Then, environmental or life style context which strongly vary between populations may play a role. Besides, other factors such as selection bias and different matching criteria may also result in the difference. In considering of the limited numbers of studies, in the future, large numbers of studies will be required to validate these associations.

Although it has been suggested the 1349 T \> G polymorphism could influence the sensitivity to ionizing radiation \[[@B50]\], it does not result in reduced endonuclease activity \[[@B18]\]. A previous meta-analysis which investigated the association of 1349 T \> G polymorphism and cancer risk suggested that the variant genotypes were associated with a moderately increased risk of all cancer types (OR = 1.09, 95% CI = 1.01-1.18 for TG versus TT; OR = 1.08, 95% CI = 1.00-1.18 for GG/TG versus TT) \[[@B51]\]. Compared with the previous study, we excluded four studies \[[@B46],[@B52]-[@B54]\] in which the 1349 T \> G genotype distributions in controls did not conform to HWE, since deviations from HWE in control subjects may bias the estimates of genetic effects in genetic association studies and meta-analysis. Besides, four additional studies with 2, 307 cases and 3, 184 control subjects in total were included in the present meta-analysis which could provide more solid evidence on the specific lack of association between *APE1*1349 T \> G polymorphism and cancer risk.. Given the power of this meta-analysis which included 14,740 cases and 20,533 controls, a false-negative finding is unlikely. However, further studies may be still needed to investigate the interactions between *APE1*polymorphism and environmental factors which play important role in carcinogenesis but were not assessed in the present meta-analysis due to lack of original data. Besides, more attention drew to the prospective −656 T \> G polymorphism in the further studies may be helpful to reveal the role of *APE1*in the etiology of cancer.

Some limitations of our meta-analysis should be addressed. Firstly, the numbers of published studies collected in our analysis were not large enough for the comprehensive analysis, especially for the *APE1*−656 T \> G polymorphism. Secondly, lacking the original data of the included studies limited our study to further evaluate the potential interactions, since gene-environment and gene-gene interactions and even different polymorphic loci of the same gene may also modulate cancer risk. Besides, our results were based on unadjusted estimates, while a more precise analysis needs to be conducted if individual data such as age and sex are available. Nevertheless, advantages in our meta-analysis should also be acknowledged. First, a systematic review of the association of *APE1*polymorphisms with cancer risk is statistically more powerful than any single study. Second, the studies included in our meta-analysis strictly and satisfactory met our selection criteria.

Conclusions
===========

In conclusion, the results from this meta-analysis suggest that the *APE1 −*656 T \> G polymorphism, but not the *APE1*1349 T \> G polymorphism may contribute to genetic susceptibility to cancer. Further prospective studies with larger numbers of unbiased-matched homogeneous patients and well-matched controls are required to validate our results and to clarify the gene-gene and gene-environment interactions between *APE1*polymorphisms and cancer risk.
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